GHRP-2 vs Pentadeca Arginate (PDA)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

GHRP-2Pentadeca Arginate (PDA)
CategoryPeptidesPeptides
Standard DoseResearch indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
TimingOn empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.Administer on an empty stomach. Inject near site of injury for localized effect.
Cycle Duration8-16 week cycles.4-12 weeks depending on therapeutic target.
Evidence Levelmoderate_humananimal_plus_anecdotal
A

GHRP-2

Peptides

Mechanism

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide GHS-R1a agonist that is the most potent of the GHRP family for GH release. It stimulates pituitary GH secretion through the ghrelin receptor while also modulating hypothalamic GHRH and somatostatin pathways. GHRP-2 increases GH, cortisol, prolactin, and ACTH release, but with less appetite stimulation than GHRP-6. It also has demonstrated anxiolytic properties and sleep-promoting effects.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.

Cycle Duration

8-16 week cycles.

Side Effects

  • Water retention
  • Moderate hunger increase (less than GHRP-6)
  • Cortisol elevation
  • Prolactin elevation
  • Tingling
  • Vivid dreams

Contraindications

  • Active cancer
  • Cushing's syndrome
  • Hyperprolactinemia
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)SermorelinBPC-157

Mechanism

Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.

Standard Dosing

Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.

Timing

Administer on an empty stomach. Inject near site of injury for localized effect.

Cycle Duration

4-12 weeks depending on therapeutic target.

Side Effects

  • Mild nausea (rare)
  • Injection site irritation
  • Headache (uncommon)

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Children under 18

Best Stacking Partners

TB-500GHK-CuCJC-1295/Ipamorelin

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →